
Tolvaptan Sodium Phosphate
Price | Get Latest Price | |
Package | 1g | 10g |
Min. Order: | 1g |
Supply Ability: | 50kg |
Update Time: | 2025-03-06 |
Product Details
Product Name: Tolvaptan Sodium Phosphate | CAS No.: 942619-79-6 |
Min. Order: 1g | Purity: 0.99 |
Supply Ability: 50kg | Release date: 2025/03/06 |
?Tolvaptan Sodium Phosphate (CAS 942619-79-6)?
?? ?ChemicalBook Product Profile?
?? ?Product Overview?
?Tolvaptan Sodium Phosphate? (C??H??ClN?NaO?P), a ?phosphate prodrug of Tolvaptan?, is a potent ?vasopressin V2 receptor antagonist? with a molecular weight of ?552.92 g/mol?. This ?white crystalline powder? (≥99.5% purity, HPLC validated) is designed for ?intravenous diuretic therapy?, particularly for patients with fluid retention who cannot tolerate oral medications. It hydrolyzes in vivo to release Tolvaptan, which selectively inhibits water reabsorption in renal tubules, promoting electrolyte-sparing diuresis. Available in ?1g/5g/100g? sealed aluminum foil packaging with ?3-year stability? under dry, light-protected conditions.
?Google Keywords?: Tolvaptan Sodium Phosphate CAS 942619-79-6, V2 Antagonist API Supplier, High-Purity Diuretic Intermediate, GMP-Certified Pharma Raw Material
? ?Key Advantages?
?? ?Ultra-High Purity?
≥99.5% purity (HPLC/NMR validated) | Complies with ?EP/USP/CP? standards.
?? ?GMP-Certified Manufacturing?Produced in ?ISO 9001? and ?GMP-compliant facilities? | REACH and ICH stability compliant.
?? ?Rapid Therapeutic Action?Achieves peak plasma concentration within ?2-4 hours? post-administration.
?? ?Application Fields?
?Diuretic Formulations?: Core API for IV therapies targeting hyponatremia and heart failure-related edema.
?Clinical Research?: Key intermediate in developing vasopressin receptor antagonists.
?Pharma Bulk Supply?: Supports global production of specialty diuretics.
?? ?Quality Certifications?
?Analytical Methods?: HPLC, NMR, mass spectrometry, microbial limit testing.
?Certifications?: ?GMP?, ?ISO 9001?, ?REACH?, and ?ICH Q1-Q12 guidelines?.
?? ?Market Trends?
The ?global diuretics market? is projected to grow at ?5.8% CAGR (2025-2030)?, driven by rising cardiovascular disorders and demand for targeted renal therapies. Tolvaptan derivatives dominate ?35% of the vasopressin antagonist segment?, with Asia-Pacific emerging as the primary API production hub.
?? ?Contact us for COA, bulk orders, and custom synthesis!
Company Profile Introduction
You may like
Recommended supplier
Product name | Price | Suppliers | Update time | |
---|---|---|---|---|
$0.00/1kg |
VIP2Y
|
Enki Biopharmaceuticals (Shanghai) Limited
|
2023-11-26 | |
$3.60/1kg |
VIP1Y
|
Hebei Andu Technology Com.,Ltd
|
2024-07-30 | |
$50.00/1KG |
VIP4Y
|
Baoji Guokang Bio-Technology Co., Ltd.
|
2021-06-03 | |
$0.00/1kg |
VIP1Y
|
Hebei Junhua Import and Export Co., LTD
|
2025-02-19 |
- Since: 2018-06-08
- Address: Biolake.858 high-tech avenue,Wuhan
+86-+undefined-+86 13343427080
sales@biocarchem.com